Electromed, Inc. (ELMD)
NYSE · Electromedical & Electrotherapeutic Apparatus · Manufacturing · CIK 1488917 · fiscal year ends in Jun
Closing price $26.89 on 30 Oct 2026; 52-week range $23.15 to $46.31.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $73.8M
- Revenue growth
- 15.3%
- Net income, last twelve months
- $11.3M
- Earnings per share
- $1.31
- Gross margin
- 78.5%
- Operating margin
- 18.8%
- Net margin
- 15.3%
- Free cash flow
- $8.4M
- Return on equity
- 20.9%
- Market value
- $225.0M
- Price to earnings
- 20.5x
- Cash
- $20.4M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 8.4M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2026 | 30 Jun 2026 | $73.8M | $13.9M | $11.3M | $1.30 | $8.4M | 10-K filed 25 Aug 2026 |
| FY2025 | 30 Jun 2025 | $64.0M | $9.7M | $7.5M | $0.85 | $11.1M | 10-K filed 26 Aug 2025 |
| FY2024 | 30 Jun 2024 | $54.7M | $6.6M | $5.2M | $0.58 | $8.8M | 10-K filed 27 Aug 2024 |
| FY2023 | 30 Jun 2023 | $48.1M | $4.0M | $3.2M | $0.36 | -$333.0K | 10-K filed 22 Aug 2023 |
| FY2022 | 30 Jun 2022 | $41.7M | $3.0M | $2.3M | $0.26 | -$2.1M | 10-K filed 23 Aug 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q4 FY2026 | 30 Jun 2026 | $19.4M | $3.4M | $0.39 |
| Q3 FY2026 | 31 Mar 2026 | $18.6M | $3.0M | $0.35 |
| Q2 FY2026 | 31 Dec 2025 | $18.9M | $2.8M | $0.32 |
| Q1 FY2026 | 30 Sep 2025 | $16.9M | $2.1M | $0.25 |
| Q4 FY2025 | 30 Jun 2025 | $17.4M | $2.2M | $0.25 |
| Q3 FY2025 | 31 Mar 2025 | $15.7M | $1.9M | $0.21 |
| Q2 FY2025 | 31 Dec 2024 | $16.3M | $2.0M | $0.22 |
| Q1 FY2025 | 30 Sep 2024 | $14.7M | $1.5M | $0.16 |
Company events
The newest 8-K filings of 141 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 25 Aug 2026 | 8-K | Results, Leadership change, Investor update | 2.02, 5.02, 7.01, 9.01 |
| 12 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 10 Feb 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 18 Dec 2025 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 18 Nov 2025 | 8-K | Shareholder vote | 5.07 |
| 12 Nov 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 9 Sep 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 26 Aug 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 13 May 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 10 Mar 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 11 Feb 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 18 Nov 2024 | 8-K | Shareholder vote, Bylaws or fiscal year change | 5.03, 5.07, 9.01 |
Every filing
The newest filings with the SEC of 303 held.
| Filed | Form | Period |
|---|---|---|
| 29 Sep 2026 | DEF 14A | 13 Nov 2026 |
| 29 Sep 2026 | DEFA14A | – |
| 29 Sep 2026 | ARS | 30 Jun 2026 |
| 25 Aug 2026 | 8-K | 25 Aug 2026 |
| 25 Aug 2026 | 10-K | 30 Jun 2026 |
| 29 May 2026 | SD | – |
| 12 May 2026 | 10-Q | 31 Mar 2026 |
| 12 May 2026 | 8-K | 12 May 2026 |
| 1 Apr 2026 | UPLOAD | – |
| 25 Mar 2026 | CORRESP | – |
| 16 Mar 2026 | UPLOAD | – |
| 10 Feb 2026 | 10-Q | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 8 Jun 2026 | Cunniff James L., CEO and President | Sale outside a trading plan | 7,003 | $36.25 | $253.9K | 150,448 | 9 Jun 2026 |
| 8 Jun 2026 | Cunniff James L., CEO and President | Sale outside a trading plan | 1,671 | $36.80 | $61.5K | 148,777 | 9 Jun 2026 |
| 8 Jun 2026 | Cunniff James L., CEO and President | Sale outside a trading plan | 1,026 | $37.77 | $38.8K | 147,751 | 9 Jun 2026 |
| 4 Jun 2026 | Nagel Bradley M., Chief Financial Officer | Sale outside a trading plan | 11,620 | $36.34 | $422.2K | 19,819 | 8 Jun 2026 |
| 4 Jun 2026 | Nagel Bradley M., Chief Financial Officer | Sale outside a trading plan | 181 | $37.11 | $6.7K | 19,638 | 8 Jun 2026 |
| 15 May 2026 | Skarvan Kathleen, Director | Sale outside a trading plan | 8,150 | $34.36 | $280.1K | 67,472 | 19 May 2026 |
| 15 May 2026 | Skarvan Kathleen, Director | Sale outside a trading plan | 19,032 | $35.24 | $670.7K | 48,440 | 19 May 2026 |
| 15 May 2026 | Skarvan Kathleen, Director | Sale outside a trading plan | 9,256 | $36.26 | $335.6K | 39,184 | 19 May 2026 |
| 15 May 2026 | Skarvan Kathleen, Director | Sale outside a trading plan | 3,562 | $37.33 | $133.0K | 35,622 | 19 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 8 Jun 2026 | Cunniff James L., Officer, Director | 9,700 | $354.1K | 8 Jun 2026 |
| 4 Jun 2026 | Nagel Bradley M., Officer | 11,801 | $428.9K | 4 Jun 2026 |
| 15 May 2026 | SKARVAN KATHLEEN, Director | 40,000 | $1.4M | 15 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 194.3K | -4.9% | 2.64 |
| 30 Sep 2026 | 204.3K | -1.21% | 2 |
| 15 Sep 2026 | 206.8K | +12.95% | 1.98 |
| 31 Aug 2026 | 183.1K | -4.16% | 1.43 |
| 14 Aug 2026 | 191.1K | +8.6% | 3.26 |
| 31 Jul 2026 | 175.9K | -9.56% | 1.8 |
| 15 Jul 2026 | 194.5K | +10.33% | 1.24 |
| 30 Jun 2026 | 176.3K | +5.29% | 1.83 |
Funds that hold it
From each fund's latest Form 13F.
135 funds held it at 30 Jun 2026: 74 added and 32 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| J.E. Simmons & Co., P.C. | 483,822 | $20.5M | -9,000 |
| BlackRock, Inc. | 465,619 | $19.7M | +6,774 |
| Vanguard Capital Management LLC | 283,232 | $12.0M | -51,796 |
| Acadian Asset Management LLC | 221,845 | $9.4M | -910 |
| Punch & Associates Investment Management, Inc. | 218,520 | $9.2M | -6,000 |
| Geode Capital Management, LLC | 217,115 | $9.2M | +15,222 |
| Dimensional Fund Advisors LP | 180,447 | $7.6M | +2,177 |
| Two Sigma Investments, LP | 167,492 | $7.1M | -36,108 |
| Hunter Associates Investment Management LLC | 155,878 | $6.6M | +5,078 |
| Gamco Investors, Inc. Et Al | 142,000 | $6.0M | 0 |
Peers
Companies in the same industry.
- Medtronic plc (MDT): revenue $37.5B, market value $123.6B
- LivaNova plc (LIVN): revenue $1.5B, market value $4.3B
- Integer Holdings Corp. (ITGR): revenue $1.8B, market value $4.3B
- Axogen, Inc. (AXGN): revenue $266.9M, market value $2.9B
- TransMedics Group, Inc. (TMDX): revenue $668.5M, market value $2.3B
- Conmed Corp. (CNMD): revenue $1.4B, market value $1.3B
- Ceribell, Inc. (CBLL): revenue $102.0M, market value $1.0B
- CapsoVision, Inc. (CV): revenue $13.9M, market value $341.7M
- Edap TMS SA (FOCL): revenue –, market value $157.6M
- Neuraxis, Inc. (NRXS): revenue $5.3M, market value $89.3M